| Literature DB >> 23734946 |
Jacob D Durrant1, Aaron J Friedman, Kathleen E Rogers, J Andrew McCammon.
Abstract
We compare established docking programs, AutoDock Vina and Schrödinger's Glide, to the recently published NNScore scoring functions. As expected, the best protocol to use in a virtual-screening project is highly dependent on the target receptor being studied. However, the mean screening performance obtained when candidate ligands are docked with Vina and rescored with NNScore 1.0 is not statistically different than the mean performance obtained when docking and scoring with Glide. We further demonstrate that the Vina and NNScore docking scores both correlate with chemical properties like small-molecule size and polarizability. Compensating for these potential biases leads to improvements in virtual screen performance. Composite NNScore-based scoring functions suited to a specific receptor further improve performance. We are hopeful that the current study will prove useful for those interested in computer-aided drug design.Entities:
Mesh:
Year: 2013 PMID: 23734946 PMCID: PMC3735370 DOI: 10.1021/ci400042y
Source DB: PubMed Journal: J Chem Inf Model ISSN: 1549-9596 Impact factor: 4.956
Areas under ROC Curves (ROC-AUC)
| receptor | Vina–Vina | Vina–NN1 | Vina–NN2 | HTVS–HTVS |
|---|---|---|---|---|
| angiotensin-converting enzyme | 0.48 | 0.69 | 0.54 | 0.45 |
| acetylcholinesterase | 0.81 | 0.90 | 0.80 | 0.87 |
| adenosine deaminase | 0.29 | 0.48 | 0.60 | 0.74 |
| aldose reductase | 0.57 | 0.63 | 0.59 | 0.61 |
| AmpC β-lactamase | 0.62 | 0.45 | 0.66 | 0.86 |
| androgen receptor | 0.67 | 0.87 | 0.71 | 0.88 |
| cyclin-dependent kinase 2 | 0.71 | 0.77 | 0.72 | 0.65 |
| catechol O-methyltransferase | 0.52 | 0.43 | 0.62 | 0.71 |
| cyclooxygenase-1 | 0.58 | 0.61 | 0.62 | 0.69 |
| cyclooxygenase-2 | 0.63 | 0.89 | 0.79 | 0.88 |
| dihydrofolate reductase | 0.78 | 0.88 | 0.85 | 0.71 |
| epidermal growth factor receptor | 0.71 | 0.76 | 0.83 | 0.68 |
| estrogen receptor agonist | 0.83 | 0.91 | 0.89 | 0.95 |
| estrogen receptor antagonist | 0.90 | 0.98 | 0.97 | 0.89 |
| fibroblast growth factor receptor kinase | 0.84 | 0.92 | 0.83 | 0.40 |
| factor Xa | 0.93 | 0.95 | 0.93 | 0.76 |
| glycinamide ribonucleotide transformylase | 0.93 | 0.88 | 0.85 | 0.51 |
| glycogen phosphorylase β | 0.38 | 0.26 | 0.25 | 0.68 |
| glucocorticoid receptor | 0.65 | 0.93 | 0.71 | 0.71 |
| HIV protease | 0.90 | 0.98 | 0.95 | 0.71 |
| HIV reverse transcriptase | 0.45 | 0.72 | 0.69 | 0.73 |
| hydroxymethylglutaryl–CoA reductase | 0.55 | 0.86 | 0.68 | 0.30 |
| human heat shock protein 90 | 0.62 | 0.90 | 0.81 | 0.78 |
| enoyl ACP reductase | 0.81 | 0.81 | 0.86 | 0.67 |
| mineralocorticoid receptor | 0.59 | 0.81 | 0.82 | 0.92 |
| neuraminidase | 0.55 | 0.56 | 0.68 | 0.91 |
| P38 mitogen activated protein | 0.87 | 0.90 | 0.92 | 0.79 |
| poly(ADP-ribose) polymerase | 0.77 | 0.73 | 0.53 | 0.95 |
| phosphodiesterase 5 | 0.82 | 0.87 | 0.88 | 0.78 |
| platelet-derived growth factor receptor kinase | 0.80 | 0.75 | 0.87 | 0.60 |
| purine nucleoside phosphorylase | 0.60 | 0.70 | 0.65 | 0.81 |
| peroxisome proliferator activated receptor γ | 0.94 | 0.96 | 0.97 | 0.73 |
| progesterone receptor | 0.72 | 0.66 | 0.67 | 0.63 |
| retinoic X receptor α | 0.59 | 0.93 | 0.87 | 0.98 |
| S-adenosyl-homocysteine hydrolase | 0.73 | 0.59 | 0.58 | 0.92 |
| tyrosine kinase SRC | 0.82 | 0.83 | 0.88 | 0.68 |
| thrombin | 0.92 | 0.95 | 0.93 | 0.84 |
| thymidine kinase | 0.46 | 0.63 | 0.60 | 0.53 |
| trypsin | 0.80 | 0.96 | 0.92 | 0.78 |
| vascular endothelial growth factor receptor | 0.84 | 0.81 | 0.88 | 0.61 |
| average | 0.70 | 0.78 | 0.76 | 0.73 |
| median | 0.72 | 0.82 | 0.81 | 0.73 |
True Positive Rates When the False Positive Rates Are Fixed at 5%
| receptors | Vina–Vina | Vina–NN1 | Vina–NN2 | HTVS–HTVS | HTVS–SP–XP | HTVS–SP–XP–NN1 | HTVS–SP–XP–NN2 | composite (general) | composite (independent) |
|---|---|---|---|---|---|---|---|---|---|
| angiotensin-converting enzyme | 0.04 | 0.25 | 0.02 | 0.10 | 0.08 | 0.10 | 0.06 | 0.24 | 0.44 |
| acetylcholinesterase | 0.40 | 0.64 | 0.25 | 0.74 | 0.69 | 0.69 | 0.65 | 0.51 | 0.66 |
| adenosine deaminase | 0.01 | 0.05 | 0.08 | 0.43 | 0.57 | 0.39 | 0.30 | 0.34 | 0.72 |
| aldose reductase | 0.02 | 0.05 | 0.16 | 0.08 | 0.08 | 0.04 | 0.08 | 0.05 | 0.70 |
| AmpC β-lactamase | 0.02 | 0.01 | 0.06 | 0.24 | 0.24 | 0.29 | 0.29 | 0.04 | 0.76 |
| androgen receptor | 0.12 | 0.39 | 0.25 | 0.54 | 0.54 | 0.57 | 0.46 | 0.20 | 0.39 |
| cyclin-dependent kinase 2 | 0.09 | 0.18 | 0.15 | 0.10 | 0.25 | 0.21 | 0.13 | 0.49 | 0.48 |
| catechol O-methyltransferase | 0.14 | 0.05 | 0.13 | 0.00 | 0.09 | 0.09 | 0.09 | 0.36 | 1.00 |
| cyclooxygenase-1 | 0.03 | 0.07 | 0.03 | 0.06 | 0.20 | 0.24 | 0.24 | 0.05 | 0.30 |
| cyclooxygenase-2 | 0.07 | 0.45 | 0.24 | 0.70 | 0.11 | 0.59 | 0.09 | 0.48 | |
| dihydrofolate reductase | 0.08 | 0.31 | 0.27 | 0.00 | 0.88 | 0.88 | 0.83 | 0.59 | |
| epidermal growth factor receptor | 0.01 | 0.09 | 0.27 | 0.15 | 0.28 | 0.28 | 0.26 | 0.27 | 0.53 |
| estrogen receptor agonist | 0.45 | 0.40 | 0.48 | 0.79 | 0.69 | 0.79 | 0.66 | 0.54 | 0.38 |
| estrogen receptor antagonist | 0.42 | 0.99 | 0.74 | 0.73 | 0.77 | 0.82 | 0.82 | 0.87 | 1.00 |
| fibroblast growth factor receptor kinase | 0.17 | 0.49 | 0.23 | 0.06 | 0.08 | 0.09 | 0.11 | 0.69 | 0.71 |
| factor Xa | 0.77 | 0.74 | 0.55 | 0.38 | 0.58 | 0.57 | 0.57 | 0.78 | 0.79 |
| glycinamide ribonucleotide transformylase | 0.50 | 0.48 | 0.04 | 0.00 | 0.86 | 0.86 | 0.81 | 1.00 | 1.00 |
| glycogen phosphorylase β | 0.02 | 0.02 | 0.01 | 0.11 | 0.17 | 0.06 | 0.00 | 0.39 | 0.75 |
| glucocorticoid receptor | 0.08 | 0.70 | 0.16 | 0.30 | 0.15 | 0.12 | 0.10 | 0.61 | 0.71 |
| HIV protease | 0.50 | 0.97 | 0.66 | 0.32 | 0.49 | 0.53 | 0.57 | 0.64 | 0.98 |
| HIV reverse transcriptase | 0.07 | 0.09 | 0.18 | 0.38 | 0.30 | 0.20 | 0.28 | 0.29 | 0.53 |
| hydroxymethylglutaryl–CoA reductase | 0.06 | 0.22 | 0.02 | 0.00 | 0.03 | 0.03 | 0.00 | 0.33 | 0.83 |
| human heat shock protein 90 | 0.01 | 0.24 | 0.23 | 0.13 | 0.17 | 0.13 | 0.21 | 0.85 | 0.73 |
| enoyl ACP reductase | 0.35 | 0.16 | 0.47 | 0.21 | 0.26 | 0.25 | 0.28 | 0.27 | 0.49 |
| mineralocorticoid receptor | 0.21 | 0.22 | 0.44 | 0.91 | 0.60 | 0.67 | 0.60 | 1.00 | 0.55 |
| neuraminidase | 0.02 | 0.05 | 0.03 | 0.81 | 0.90 | 0.69 | 0.65 | 0.47 | 0.95 |
| P38 mitogen-activated protein | 0.46 | 0.53 | 0.53 | 0.43 | 0.46 | 0.48 | 0.47 | 0.43 | 0.48 |
| poly(ADP-ribose) polymerase | 0.06 | 0.10 | 0.05 | 0.67 | 0.45 | 0.52 | 0.30 | 0.29 | 0.33 |
| phosphodiesterase 5 | 0.26 | 0.42 | 0.46 | 0.32 | 0.31 | 0.39 | 0.35 | 0.55 | 0.64 |
| platelet-derived growth factor receptor kinase | 0.20 | 0.18 | 0.46 | 0.09 | 0.08 | 0.10 | 0.11 | 0.32 | 0.40 |
| purine nucleoside phosphorylase | 0.06 | 0.17 | 0.16 | 0.56 | 0.48 | 0.40 | 0.40 | 0.33 | 0.88 |
| peroxisome proliferator activated receptor γ | 0.82 | 0.81 | 0.87 | 0.41 | 0.62 | 0.58 | 0.57 | 0.78 | 0.97 |
| progesterone receptor | 0.10 | 0.31 | 0.14 | 0.05 | 0.00 | 0.04 | 0.00 | 0.16 | 0.35 |
| retinoic X receptor α | 0.20 | 0.74 | 0.42 | 0.80 | 0.50 | 0.45 | 0.45 | 1.00 | 1.00 |
| S-adenosyl-homocysteine hydrolase | 0.03 | 0.05 | 0.02 | 0.73 | 0.48 | 0.09 | 0.42 | 0.44 | 0.82 |
| tyrosine kinase SRC | 0.11 | 0.30 | 0.25 | 0.33 | 0.48 | 0.44 | 0.50 | 0.44 | 0.60 |
| thrombin | 0.65 | 0.74 | 0.60 | 0.46 | 0.77 | 0.78 | 0.77 | 0.95 | 0.84 |
| thymidine kinase | 0.01 | 0.15 | 0.08 | 0.09 | 0.14 | 0.14 | 0.09 | 0.36 | 0.76 |
| trypsin | 0.48 | 0.88 | 0.46 | 0.45 | 0.80 | 0.77 | 0.80 | 0.73 | 1.00 |
| vascular endothelial growth factor receptor | 0.24 | 0.25 | 0.50 | 0.27 | 0.27 | 0.27 | 0.33 | 0.33 | 0.66 |
| average | 0.21 | 0.35 | 0.28 | 0.35 | 0.39 | 0.38 | 0.38 | 0.48 | 0.68 |
| median | 0.10 | 0.25 | 0.24 | 0.32 | 0.38 | 0.34 | 0.34 | 0.43 | 0.70 |
R2 (Goodness of Fit) Values Associated with Correlations between Average Rank Over All 40 Receptors and Selected NCI Small-Molecule Chemical Properties, As Determined Using Schrödinger’s Qikpropa
| Qikprop Property | Vina–Vina | Vina–NN1 | Vina–NN2 | HTVS–HTVS | HTVS–SP–XP |
|---|---|---|---|---|---|
| molecular weight | 0.45 | 0.42 | 0.48 | 0.03 | 0.20 |
| solvent-accessible surface area (Å2) | 0.43 | 0.48 | 0.44 | 0.02 | 0.15 |
| solvent-accessible volume (Å3) | 0.44 | 0.52 | 0.45 | 0.02 | 0.16 |
| polarizability (Å3) | 0.57 | 0.52 | 0.54 | 0.05 | 0.10 |
| predicted hexadecane/gas partition coefficient | 0.56 | 0.41 | 0.51 | 0.06 | 0.24 |
| number of atoms in rings | 0.70 | 0.32 | 0.50 | 0.23 | 0.07 |
| number of heteroatoms | 0.57 | 0.50 | 0.49 | 0.05 | 0.21 |
For the HTVS–SP–XP protocol, only ligands that were scored using Glide XP in at least 10 out of 40 receptors were considered. In the end, this amounted to about 200 ligands.
Figure 1Molecular properties vs average experimentally measured pKi values independent of the receptor. Linear regression is shown as a bolded line. (A) Molecular weight. (B) Polarizability.
Figure 2Screen performance when composite scoring functions were used. In each graph, the leftmost data point describes the average performance over all 40 DUD receptors when a composite function that incorporates the Vina–NN1 score together with 15 small-molecule properties is used. Advancing rightward, composite functions are used that progressively incorporate fewer chemical properties. The rightmost data point shows screen performance when Vina–NN1 alone is used. (A) Single general-purpose function. (B) Independent composite scoring functions generated for each receptor.